Pharmacological preconditioning with monophosphoryl lipid A improves post ischemic diastolic function and modifies TNF-alpha synthesis

European Journal of Cardio-thoracic Surgery

Volumn 27, Issue 3, 2005, Pages 501-507

  Sharony, Ram ^a   Frolkis, Inna ^a   Froylich, Dvir ^a   Wildhirt, Stephan M ^b   Shapira, Itzhak ^a   Reichart, Bruno ^b   Nesher, Nahum ^a   Uretzky, Gideon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Ischemia reperfusion; Preconditioning; TNF alpha

Indexed keywords

MESSENGER RNA; PHOSPHORYL LIPID A; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR PERFORMANCE; CONTROLLED STUDY; DIASTOLE; DRUG EFFECT; HEART INFARCTION PREVENTION; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE FUNCTION; IMMUNOHISTOCHEMISTRY; ISOLATED HEART; MALE; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; SPECIES COMPARISON; SYSTOLE;

ANIMALS; CORONARY CIRCULATION; GENE EXPRESSION REGULATION; HEMODYNAMIC PROCESSES; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LIPID A; MALE; MYOCARDIAL REPERFUSION INJURY; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 14644403618     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2004.11.033     Document Type: Article

References (25)

1. K. Julier, R. da Silva, C. Garcia, L. Bestmann, P. Frascarolo, A. Zollinger, P.G. Chassot, E.R. Schmid, M.I. Turina, L.K. von Segesser, T. Pasch, D.R. Spahn, and M. Zaugg Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study Anesthesiology 98 6 2003 1315 1327
2. J. Laurikka, Z.K. Wu, P. Iisalo, L. Kaukinen, E.L. Honkonen, S. Kaukinen, and M.R. Tarkka Regional ischemic preconditioning enhances myocardial performance in off-pump coronary artery bypass grafting Chest 121 4 2002 1183 1189
3. G.F. Baxter, R.J. Heads, and D.M. Yellon Oxidative stress and the second window of protection after preconditioning Circulation 94 11 1996 2992 2993
4. G.F. Baxter Role of adenosine in delayed preconditioning of myocardium Cardiovasc Res 55 3 2002 483 494
5. A. Valtchanova-Matchouganska, M. Gondwe, and A. Nadar The role of C-reactive protein in ischemia/reperfusion injury and preconditioning in a rat model of myocardial infarction Life Sci 75 8 2004 901 910
6. A. Vegh, K. Gyorgy, M.A. Rastegar, J.G. Papp, and J.R. Parratt Delayed protection against ventricular arrhythmias by monophosphoryl lipid-A in a canine model of ischaemia and reperfusion Eur J Pharmacol 382 2 1999 81 90
7. K.J. Drachenberg, M. Heinzkill, E. Urban, and S.R. Woroniecki Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents Allergol Immunopathol (Madr) 31 5 2003 270 277
8. J. Gurevitch, I. Frolkis, Y. Yuhas, Y. Paz, M. Matsa, R. Mohr, and V. Yakirevich Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion J Am Coll Cardiol 28 1 1996 247 252
9. D.R. Meldrum, C.A. Dinarello, B.D. Shames, J.C. Cleveland Jr, B.S. Cain, A. Banerjee, X. Meng, and A.H. Harken Ischemic preconditioning decreases postischemic myocardial tumor necrosis factor-alpha production. Potential ultimate effector mechanism of preconditioning Circulation 98 Suppl. 19 1998 II214 II218 [discussion II218-9]
10. S.Y. He, H.W. Deng, and Y.J. Li Monophosphoryl lipid A-induced delayed preconditioning is mediated by calcitonin gene-related peptide Eur J Pharmacol 420 2-3 2001 143 149
11. A. Tosaki, N. Maulik, G.T. Elliott, I.E. Blasig, R.M. Engelman, and D.K. Das Preconditioning of rat heart with monophosphoryl lipid A: a role for nitric oxide J Pharmacol Exp Ther 285 3 1998 1274 1279
12. M.E. Astiz, E.C. Rackow, J.G. Still, S.T. Howell, A. Cato, K.B. Von Eschen, J.T. Ulrich, J.A. Rudbach, G. McMahon, R. Vargas, and W. Stern Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial Crit Care Med 23 1 1995 9 17
13. G.T. Elliott Monophosphoryl lipid A induces delayed preconditioning against cardiac ischemia-reperfusion injury J Mol Cell Cardiol 30 1 1998 3 17
14. S. Kapadia, J. Lee, G. Torre-Amione, H.H. Birdsall, T.S. Ma, and D.L. Mann Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration J Clin Invest 96 2 1995 1042 1052
15. M. Funahashi Effects of ischemic preconditioning on myocardial protective on cardiac surgery: possibility of ischemic preconditioning and adenosine administration Ann Thorac Cardiovasc Surg 9 5 2003 307 313
16. M.A. Leesar, M.F. Stoddard, Y.T. Xuan, X.L. Tang, and R. Bolli Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans J Am Coll Cardiol 42 3 2003 437 445
17. G.T. Elliott, M.L. Comerford, J.R. Smith, and L. Zhao Myocardial ischemia/reperfusion protection using monophosphoryl lipid A is abrogated by the ATP-sensitive potassium channel blocker, glibenclamide Cardiovasc Res 32 6 1996 1071 1080
18. R. Bolli Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research J Mol Cell Cardiol 33 11 2001 1897 1918
19. P. Ferdinandy, H. Danial, I. Ambrus, R.A. Rothery, and R. Schulz Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure Circ Res 87 3 2000 241 247
20. S. Lecour, R.M. Smith, B. Woodward, L.H. Opie, L. Rochette, and M.N. Sack Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection J Mol Cell Cardiol 34 5 2002 509 518
21. G.F. Baxter, and D.M. Yellon Delayed myocardial protection following ischaemic preconditioning Basic Res Cardiol 91 1 1996 53 56
22. P.S. Cohen, H. Nakshatri, J. Dennis, T. Caragine, M. Bianchi, A. Cerami, and K.J. Tracey CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency Proc Natl Acad Sci USA 93 9 1996 3967 3971
23. T. Mijatovic, L. Houzet, P. Defrance, L. Droogmans, G. Huez, and V. Kruys Tumor necrosis factor-alpha mRNA remains unstable and hypoadenylated upon stimulation of macrophages by lipopolysaccharides Eur J Biochem 267 19 2000 6004 6012
24. R.A. Kloner, T. Shook, K. Przyklenk, V.G. Davis, L. Junio, R.V. Matthews, S. Burstein, M. Gibson, W.K. Poole, C.P. Cannon, C.H. McCabe, and E. Braunwald Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 91 1 1995 37 45
25. X. Wang, M. Wei, J. Laurikka, P. Kuukasjarvi, T. Rinne, E.L. Honkonen, R. Nieminen, E. Moilanen, and M. Tarkka The anti-inflammatory effect of diazoxide in coronary artery bypass grafting Shock 22 1 2004 23 28